Browsing publications by Dr Elaine Willmore

Newcastle AuthorsTitleYear
Emily Mould
Philip Berry
Dr David Jamieson
Dr Chris Hill
Dr Celine Cano
et al.
Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity2014
Pawel Znojek
Dr Elaine Willmore
Professor Nicola Curtin
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase2014
Emily Mould
Philip Berry
Dr David Jamieson
Dr Chris Hill
Niu Tan
et al.
The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells2013
Shilu Amin
Dr Meagan Walsh
Dr Caroline Wilson
Dr Elaine Willmore
Professor Derek Mann
et al.
Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL2012
Dr Elaine Willmore
Natalie Rodrigues
Dr Jonathan Wallis
Professor Nicola Curtin
High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia2012
Dr Jill Hunter
Dr Elaine Willmore
Dr Julie Irving
Dr Stephany Veuger
Emeritus Professor Barbara Durkacz
et al.
NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-0146992012
Dr Susan Tudhope
Dr Evan Mulligan
Dr Jill Hunter
Dr Helen Marr
Emeritus Professor Barbara Durkacz
et al.
P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells2012
Dr Sarah Johnson
Clark Crawford
Dr Evan Mulligan
Dr Jonathan Wallis
Dr Tryfonia Mainou-Fowler
et al.
Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia2011
Dr Elaine Willmore
Dr Evan Mulligan
Dr Sarah Elliott
Emeritus Professor Barbara Durkacz
ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA Dependent Protein Kinase2010
Dr Sarah Johnson
Dr Tryfonia Mainou-Fowler
Emeritus Professor Barbara Durkacz
Dr Elaine Willmore
Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for poor risk B-cell chronic lymphocytic leukaemia2010
1234